M72
ENEA Technology
DEVELOPMENT AND ASSESSMENT OF THE IMMUNO-MODULATING ACTIVITY OF BIOTECH PRODUCTS, SMALL MOLECULES AND OTHER IMMUNO-THERAPEUTICS
Technology Readiness Level (TRL)
5÷7
Innovations and Benefits
In recent years, the open innovation model, characterized by cooperative interactions between research institutes and pharmaceutical industries, strengthened the development of innovative pharmaceuticals. The immunology area represents one of the most interesting areas for biotech companies.
ENEA has skills, knowledge and experimental models that can foster pharmaceutical companies and other stakeholders in the development of immuno-modulating drugs by using and/or developing innovative assays with procedures shifted from the basic research. ENEA also supports technology transfer to companies where, assays developed by ENEA, can be implemented to adhere to GLP and/or GMP procedures.
Use
Pharmaceutical and biotech companies, including SMEs, and other stakeholders to:
• assess the immunological effects of biopharmaceuticals and small molecules;
• assess the immuno-modulating properties of natural products;
• assess the therapeutic effects in experimental models for immuno-mediated diseases;
• assessments to complement analysis required for regulatory/autorizathion processes;
• development of innovative assays with procedures translated from basic research.
Applications and ongoing Activities
Collaborations with Research Toxicology Center (RTC) SpA (Menarini Group) to assess the activity of biological and biotechnology products using immunological assays and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A to assess the pharmacological activity of small molecules in graft vs. host disease models.
“If you are interested in this technology/service, please send a message to eneaperlinnovazione@enea.it, by specifying the title of the technology/service of your interest, the reason for your request and your contacts or the contacts of a person from your organization/company.
